AU764370B2 - Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects - Google Patents

Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects Download PDF

Info

Publication number
AU764370B2
AU764370B2 AU50833/99A AU5083399A AU764370B2 AU 764370 B2 AU764370 B2 AU 764370B2 AU 50833/99 A AU50833/99 A AU 50833/99A AU 5083399 A AU5083399 A AU 5083399A AU 764370 B2 AU764370 B2 AU 764370B2
Authority
AU
Australia
Prior art keywords
cpt
cancer
camptothecin
uptake
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU50833/99A
Other languages
English (en)
Other versions
AU5083399A (en
Inventor
Bernard Bouscarel
Kunihiko Kobayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
George Washington University
Original Assignee
George Washington University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Washington University filed Critical George Washington University
Publication of AU5083399A publication Critical patent/AU5083399A/en
Application granted granted Critical
Publication of AU764370B2 publication Critical patent/AU764370B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU50833/99A 1998-06-18 1999-06-18 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects Ceased AU764370B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8978198P 1998-06-18 1998-06-18
US60/089781 1998-06-18
PCT/US1999/013906 WO1999065493A1 (en) 1998-06-18 1999-06-18 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects

Publications (2)

Publication Number Publication Date
AU5083399A AU5083399A (en) 2000-01-05
AU764370B2 true AU764370B2 (en) 2003-08-14

Family

ID=22219554

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50833/99A Ceased AU764370B2 (en) 1998-06-18 1999-06-18 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects

Country Status (7)

Country Link
EP (1) EP1003516A4 (de)
JP (1) JP2002518332A (de)
CN (1) CN1325305A (de)
AU (1) AU764370B2 (de)
CA (1) CA2300892A1 (de)
IL (1) IL134592A0 (de)
WO (1) WO1999065493A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1003516A4 (de) * 1998-06-18 2006-07-12 Univ George Washington Verfahren zur verabreichung von camptothecin verbindungen zur krebsbehandlung mit verringerten nebenwirkungen
ES2270834T3 (es) 1999-05-17 2007-04-16 Cancer Research Ventures Limited Composiciones para mejorar la biodisponibilidad de farmacos administrados oralmente.
CA2295429A1 (en) * 2000-01-06 2001-07-06 Michael Michael Treatment or prevention of diarrhea
WO2002074246A2 (en) * 2001-03-20 2002-09-26 New Century Pharmaceuticals, Inc. Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
US8410045B2 (en) 2006-03-30 2013-04-02 Drais Pharmaceuticals, Inc. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
AU2007306139B2 (en) * 2006-10-11 2014-02-27 Fusion Antibodies Limited Combination therapy
US20170246190A1 (en) * 2014-10-21 2017-08-31 Johnpro Biotech Inc. Methods and formulation for improving oral availability of cpt-11 while reducing cpt-11 induced gastrointestinal toxicity in cancer therapy
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
CN107281462A (zh) * 2017-08-21 2017-10-24 滨州医学院 沙奎拉韦减轻伊立替康毒性的医药新用途
US11000540B1 (en) * 2019-11-22 2021-05-11 Al Siamon Treatment for reducing adverse events including chemotherapy discomfort and other conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5859022A (en) * 1995-06-05 1999-01-12 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
WO1999065493A1 (en) * 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894029A (en) * 1971-08-26 1975-07-08 Basf Ag Production of camptothecin and camptothecin-like compounds
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
AU634746B2 (en) * 1989-02-07 1993-03-04 Dimminaco Ag/Sa/Ltd. Effervescent composition for oral rehydration
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
WO1996011005A2 (en) * 1994-10-06 1996-04-18 Atlas Leon T Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
JPH10201821A (ja) * 1997-01-23 1998-08-04 Material Eng Tech Lab Inc 医療用容器

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5859022A (en) * 1995-06-05 1999-01-12 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
WO1999065493A1 (en) * 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects

Also Published As

Publication number Publication date
IL134592A0 (en) 2001-04-30
EP1003516A4 (de) 2006-07-12
CA2300892A1 (en) 1999-12-23
WO1999065493A1 (en) 1999-12-23
AU5083399A (en) 2000-01-05
WO1999065493A9 (en) 2000-03-23
EP1003516A1 (de) 2000-05-31
CN1325305A (zh) 2001-12-05
JP2002518332A (ja) 2002-06-25

Similar Documents

Publication Publication Date Title
US6635628B2 (en) Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
US5726181A (en) Formulations and compositions of poorly water soluble camptothecin derivatives
US5633260A (en) 11,7 Substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
Mathijssen et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
US5447936A (en) Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
AU671605B2 (en) Combination chemotherapy
Emerson et al. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues
Kehrer et al. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies
TWI307277B (en) Parenteral formulations
AU764370B2 (en) Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
Kobayashi et al. pH‐dependent uptake of irinotecan and its active metabolite, SN‐38, by intestinal cells
Burris III et al. Topoisomerase I inhibitors: an overview of the camptothecin analogs
Dahut et al. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.
Supko et al. Pharmacokinetics of the 9-amino and 10, 11-methylenedioxy derivatives of camptothecin in mice
Saif et al. Edotecarin: a novel topoisomerase I inhibitor
EP1214078B1 (de) Parenteral anzuwendende arzneizusammensetzungen enthaltend estramustinphosphat und aminosäure
Wadkins et al. Water soluble 20 (S)-glycinate esters of 10, 11-methylenedioxycamptothecins are highly active against human breast cancer xenografts
Mross et al. A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors
Gilbert et al. 9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs
Brouwers et al. Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate
MXPA00001702A (en) Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
Saotome et al. Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma
US20040204435A1 (en) Alternating treatment with topoisomerase I and topoisomerase II inhibitors
ITMI991998A1 (it) Formulazioni di estramustina fosfato ed albumina per uso parenterale
Flaherty et al. The clinical development of lurtotecan: experience with water-soluble and liposomal forms

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)